ABT FY 2020 Earnings Report — Abbott Laboratories Revenue & Financial Results | Market Cap Arena

Abbott LaboratoriesABT

FY 2020 Earnings

Reported February 19, 2021

Quarter Comparison

Revenue

Operating Income

Gross Margin

Net Margin

EPS (Diluted)

Free Cash Flow

Metric	FY 2020	Prior Q	FY 2019	QoQ Change	YoY Change
Revenue	$34.6B	—	$31.9B	—	8.5%
Op. Income	$5.3B	—	$4.6B	—	15.2%
Gross Margin	50.2%	—	52.3%	—	-2.1pp
Net Margin	13.0%	—	11.6%	—	1.4pp
EPS (Diluted)	$2.50	—	$2.06	—	21.4%
Free Cash Flow	$5.7B	—	$4.5B	—	27.3%

Revenue Flow

Item	Amount
REVENUE	$34.6B
Cost of Revenue	$17.2B
GROSS PROFIT	$17.4B
R&D Expenses	$2.4B
Selling & Marketing	$0
General & Administrative	$0
SG&A Expenses	$9.7B
Other Expenses	$0
Operating Expenses	$12.1B
Cost & Expenses	$29.3B
OPERATING INCOME	$5.3B
Interest Income	$46M
Interest Expense	$708M
Other Income/Expenses	-$323M
INCOME BEFORE TAX	$5.0B
Income Tax Expense	$497M
Net Income from Continuing Ops	$4.5B
Net Income from Discontinued Ops	$24M
Other Adjustments	$0
NET INCOME	$4.5B
Net Income Deductions	$0
BOTTOM LINE NET INCOME	$4.5B
D&A	$3.3B
EBIT	$5.7B
EBITDA	$9.0B
EPS	$3
EPS Diluted	$3

Income Statement

Item	Amount
REVENUE	$34.6B
Cost of Revenue	$17.2B
GROSS PROFIT	$17.4B
R&D Expenses	$2.4B
Selling & Marketing	$0
General & Administrative	$0
SG&A Expenses	$9.7B
Other Expenses	$0
Operating Expenses	$12.1B
Cost & Expenses	$29.3B
OPERATING INCOME	$5.3B
Interest Income	$46M
Interest Expense	$708M
Other Income/Expenses	-$323M
INCOME BEFORE TAX	$5.0B
Income Tax Expense	$497M
Net Income from Continuing Ops	$4.5B
Net Income from Discontinued Ops	$24M
Other Adjustments	$0
NET INCOME	$4.5B
Net Income Deductions	$0
BOTTOM LINE NET INCOME	$4.5B
D&A	$3.3B
EBIT	$5.7B
EBITDA	$9.0B
EPS	$3
EPS Diluted	$3

Cash Flow Statement

Item	Amount
Net Income	$4.5B
Depreciation & Amortization	$3.3B
Stock-Based Compensation	$546M
Deferred Income Tax	$0
Other Non-Cash Items	$425M
Change in Working Capital	-$892M
OPERATING CASH FLOW	$7.9B
Capital Expenditure	-$2.2B
Acquisitions (Net)	$16M
Purchases of Investments	-$83M
Sales/Maturities of Investments	$10M
Other Investing Activities	$19M
NET CASH FROM INVESTING	-$2.2B
Net Debt Issuance	-$50M
Common Stock Repurchased	-$403M
Common Dividends Paid	-$2.6B
Other Financing Activities	$234M
NET CASH FROM FINANCING	-$2.8B
FREE CASH FLOW	$5.7B
Net Change in Cash	$3.0B

Balance Sheet

Item	Amount
Cash & Equivalents	$6.8B
Short-Term Investments	$310M
Net Receivables	$6.4B
Inventory	$5.0B
Other Current Assets	$1.9B
TOTAL CURRENT ASSETS	$20.4B
PP&E (Net)	$10.1B
Goodwill	$23.7B
Intangible Assets	$14.8B
Long-Term Investments	$1.0B
Tax Assets	$0
Other Non-Current Assets	$2.4B
TOTAL NON-CURRENT ASSETS	$52.1B
TOTAL ASSETS	$72.5B
Account Payables	$3.9B
Short-Term Debt	$461M
Deferred Revenue	$0
Other Current Liabilities	$5.7B
TOTAL CURRENT LIABILITIES	$11.9B
Long-Term Debt	$18.5B
Deferred Revenue NC	$0
Deferred Tax Liabilities	$2.1B
Other Non-Current Liabilities	$6.1B
TOTAL NON-CURRENT LIABILITIES	$27.6B
TOTAL LIABILITIES	$39.5B
Common Stock	$24.1B
Additional Paid-In Capital	$0
Retained Earnings	$27.6B
Treasury Stock	-$10.0B
Accum. Other Comp. Income	-$8.9B
Other Equity	$0
TOTAL STOCKHOLDERS' EQUITY	$32.8B
Minority Interest	$219M
TOTAL EQUITY	$33.0B
TOTAL LIABILITIES & EQUITY	$72.5B
Total Debt	$19.9B
Net Debt	$13.1B